8-K: Assertio Secures Long-Term ROLVEDON Supply Pricing

Assertio Holdings' subsidiary, Spectrum Pharmaceuticals, amended its supply agreement for ROLVEDON drug substance, securing a mid-single digit price reduction and long-term pricing.

Summary

• Spectrum Pharmaceuticals, Inc., a wholly owned subsidiary of Assertio Holdings, Inc., and Hanmi Pharmaceutical Co. Ltd. (the Supplier) entered into an amendment and restatement of their Supply Agreement on October 7, 2025.
• The amendment establishes long-term pricing for ROLVEDON drug substance following the expiration of the previous fixed pricing provisions in October 2025.
• The new agreement reflects a mid-single digit percentage reduction to the price Spectrum agreed to pay the Supplier for ROLVEDON drug substance.
• The new price is fixed throughout the remaining term of Spectrum's license agreement with the Supplier.
• The Supplier has the right to request price increases for periods beginning January 1, 2028, if it experiences cost increases above a set threshold.
• Per gram pricing will be reduced by a specified amount for each year in which the previous year's global market volume for ROLVEDON exceeds a specified threshold, which has not yet been met.
• Spectrum's consent is required for any changes to the Supplier's manufacturing process, allowing Spectrum to negotiate lower supply prices as a condition for approving cost-reducing process improvements.
• Spectrum is required to provide the Supplier with an annual forecasted purchase plan, and while there are no minimum purchase requirements, at least fifty percent of any included orders must be designated as binding.

Sentiment

Score: 7

Explanation: The amendment is largely positive, securing a price reduction and long-term stability for a key drug substance. While there are future price increase clauses and volume thresholds not yet met, the immediate financial benefit and supply security are favorable.

Positives

• Secured a mid-single digit percentage reduction in the price paid for ROLVEDON drug substance, improving cost of goods sold.
• Established fixed long-term pricing for the remaining term of the license agreement, providing cost predictability and stability.
• Retained control over manufacturing process changes, allowing for potential future price negotiations if the Supplier's costs decrease.
• Ensures continued supply of a critical drug substance, ROLVEDON, for the company's product.

Negatives

• The Supplier retains the right to request price increases from January 1, 2028, if its costs rise above a set threshold.
• A provision for further price reduction based on global market volume for ROLVEDON has not yet been met, indicating current sales volumes are below this threshold.
• Fifty percent of forecasted purchase orders must be designated as binding, introducing a level of commitment without a minimum purchase requirement.

Risks

• Potential for supplier-initiated price increases for ROLVEDON drug substance from January 1, 2028, which could impact future margins.
• Reliance on a single supplier (Hanmi Pharmaceutical Co. Ltd.) for ROLVEDON drug substance, posing supply chain risk.
• The specified global market volume threshold for further price reductions has not yet been met, indicating that achieving this benefit is contingent on future sales growth.

Future Outlook

The new pricing structure for ROLVEDON drug substance is fixed for the remaining term of Spectrum's license agreement. While the supplier can request price increases from January 1, 2028, based on cost increases, there is also a potential for further price reductions if global market volume for ROLVEDON exceeds a specified threshold, which has not yet been met. Spectrum also retains leverage to negotiate lower prices for approving future manufacturing process improvements.

Management Comments

• The Amendment reflects a mid-single digit percentage reduction to the price Spectrum agreed to pay the Supplier for ROLVEDON drug substance following the Company's acquisition of Spectrum in 2023.

Industry Context

Securing long-term supply agreements with favorable pricing is a critical aspect of supply chain management in the pharmaceutical industry, particularly for proprietary drug substances. This amendment helps Assertio Holdings manage its cost of goods sold for ROLVEDON, a key product, and provides stability in its manufacturing costs, aligning with broader industry efforts to optimize supply chains and mitigate raw material price volatility.

Comparison to Industry Standards

• Securing a mid-single digit price reduction on a key drug substance supply agreement is generally considered a favorable outcome in the pharmaceutical industry, especially for a proprietary drug like ROLVEDON, as it helps manage COGS and improve margin stability.
• The inclusion of clauses allowing for future price adjustments based on supplier cost increases or global volume thresholds is a common mechanism in long-term pharmaceutical supply contracts, balancing supplier and buyer interests.
• Maintaining consent rights over manufacturing process changes is a standard practice for pharmaceutical companies to ensure quality control and leverage for future negotiations, comparable to agreements seen with companies like Pfizer or Merck for their critical component supplies.

Stakeholder Impact

• Shareholders: Potential for improved margins and financial predictability due to reduced cost of goods sold for ROLVEDON, which could positively impact profitability and shareholder value.
• Customers: Ensures continued and stable supply of ROLVEDON, supporting product availability and reliability.
• Employees: Stable supply chain and improved financial health can contribute to overall company stability.

Next Steps

• The Amendment will be filed as an exhibit to Assertio Holdings, Inc.'s Annual Report on Form 10-K for the year ending December 31, 2025.

Key Dates

Recommendation

The amendment to the ROLVEDON supply agreement, securing a mid-single digit price reduction and long-term fixed pricing, is a positive development for Assertio Holdings. This improves cost predictability and potentially enhances margins for a key product, signaling improved operational efficiency and financial stability. While there are future price adjustment clauses, the immediate benefit of cost reduction and supply security warrants a positive outlook for the company's financial performance and stock.

Keywords

Assertio Holdings, Spectrum Pharmaceuticals, Hanmi Pharmaceutical, ROLVEDON, Supply Agreement, Drug Substance, Pharmaceutical, Pricing, SEC Filing, 8-K